laboratori corp america hldg
consolid thesi back focu
oper solid start
labcorp post solid start help affirm convict enterpris
strategi challeng close labcorp deliv lab revenu beat
overal ep beat vs expect diagnost better expect
headlin organ volum growth beat model data
point reinforc underli lab oper environ remain sound
covanc headlin revenu miss expect drove overal top-lin miss
though attribut weaker pass-through revenu view strictli
optic revenu associ margin labcorp note underli covanc
organ revenu within full-year guidanc rang believ
underli perform valid covanc strong earn growth post
adjust ebit growth margin expans labcorp reiter
revenu outlook rais ep guid
believ net share gain nation payor back focu nation
lab appear leverag scale advantag amid industri pressur nation
lab share gain thesi long time given industri fragment
scale advantag inher strategi coupl pama reimburs
pressur think broader access nation payor help remov histor
barrier consolid labcorp size net headwind manag care
payor shift headwind lab revenu around labcorp note
initi lost share stabil aetna volum
built throughout quarter quest size net tailwind payor shift
around revenu growth around quest note initi gain
share januari continu build throughout quarter
base compani commentari believ nation lab collect
gain share start around net benefit
believ labcorp busi model well posit consolid share
time across diagnost drug develop given uniqu scale enterpris
capabl reiter overweight rate rais pt
lh quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
barclay laboratori corp america hldg
laboratori corp america hldg lh
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight labcorp good track record
execut led solid organ growth
augment value-enhanc acquisit
time expect labcorp scale advantag across
diagnost drug develop gain share
substanti free cash flow use
augment growth
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceler revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ep
barclay laboratori corp america hldg
labcorp post solid start help affirm convict compani
enterpris strategi challeng close labcorp deliv lab revenu
beat overal ep beat rel expect vs forecast
diagnost better expect headlin organ volum growth
beat model data point reinforc underli lab oper
environ remain sound covanc headlin revenu miss expect
drove overal top-lin miss though attribut weaker pass-through revenu
covanc view strictli optic revenu associ margin
adjust factor labcorp note covanc organ revenu within full-
year guidanc rang believ underli perform valid
covanc strong earn growth post adjust ebit growth margin
expans labcorp reiter revenu outlook modestli
rais ep forecast flow quarterli
beat final labcorp util free cash flow buy back share
author remain quarter end
believ net share gain nation payor back focu nation lab
appear leverag scale advantag amid industri pressur nation lab
share gain thesi long time given industri fragment scale
advantag inher strategi coupl pama reimburs pressur think
broader access nation payor help remov histor barrier consolid
labcorp size net headwind manag care payor shift
headwind lab revenu around labcorp note initi lost share
stabil aetna volum built throughout quarter
quest size net tailwind payor shift around revenu growth around
quest note initi gain share januari
continu build throughout quarter base compani commentari believ
nation lab collect gain share start around
believ labcorp busi model well posit consolid share
time across diagnost drug develop given uniqu scale enterpris
capabl reiter overweight rate rais price target
given better convict modestli higher outlook rais price target
price target repres ep forecast
prior price target repres prior ep forecast
labcorp maintain compani revenu guidanc modestli
rais ep forecast view encourag signal
compani good start revenu growth expect rang
emb headwind net impact acquisit
divestitur well headwind fx embed guidanc half year
revenu acquir envigo busi labcorp diagnost expect show
total growth embed growth rate headwind
divestitur headwind fx headwind pama
clf medicaid addit keep mind payor contract
chang unitedhealthcar aetna horizon net headwind
manag impli would volum model organ volum
barclay laboratori corp america hldg
anticip flat slightli covanc revenu growth expect
rang headwind fx result organ growth guidanc
ep guidanc repres growth y/i increas
previous labcorp expect ep headwind
pama impact cyber secur invest compani
forecast tax rate free cash flow guidanc
initi million capital-expenditure anticip repres revenu
pleas see report
risk/reward new payor
paradigm upgrad ow
net headwind open payor network aetna
part cover steve valiquett headwind volum
better expect assum headwind
quarter ceo dave king note unitedhealthcar share loss larg concentr
januari stabil toward end quarter convers mention
aetna volum continu build march
guidanc dx dx dx organ organ growth barclay laboratori corp america hldg
diagnost januari mark offici open unit horizon aetna exclus put us network
major nation plan although saw expect volum declin januari pleas perform
abil gener organ volum growth despit lose exclus major plan project
unit horizon volum declin januari partial off-set aetna gain stabl throughout rest
pleas retent unit busi team mention prepar remark
absolut outstand job get front custom continu demonstr valu labcorp bring
retain busi pleas retent horizon busi team particularli
northeast divis outstand job top bottom everybodi divis retain busi
aetna growth strong actual continu increas throughout quarter
focu ad valu
continu see renew end exclus contract nation payer
real strateg posit nation lab labcorp quest remind
labcorp quest recent announc new contract aetna
view game-chang industri previous labcorp quest exclus
relationship aetna respect open
januari overal believ new contract help break barrier
nation lab consolid share test improv patient experi
payor believ net yield modest benefit quest modest
headwind labcorp simpl math fact larger
aetna would suggest quest net beneficiari vice versa labcorp said
fact labcorp earn price increas critic
element deal calculu also cement truli paradigm shift
final see anoth catalyst juli implement prefer
laboratori network earlier month announc addit detail
payor prefer lab network pln time view increment
opportun labcorp quest leverag scale advantag earn share
lab test remind pln origin announc decemb
slate go effect juli pln subset in-network
provid includ lab quest ameripath subsidiari labcorp bio-refer
genedx subsidiari cover invita cover mayo lab
privat believ cover full menu test given lab commentari mix
routin advanc test provid chang network statu
lab provid said nation lab previous comment
potenti econom incent physician patient choos prefer provid
 lower pocket expens benefit design chang may go
effect await addit visibl lab
strength incent order gaug potenti share shift
barclay laboratori corp america hldg
commentari prefer lab network
newli establish prefer laboratori network pln physician patient like receiv
better health care valu improv access qualiti servic lower cost creation pln
advanc way work select lab provid deliv care place greater emphasi patient outcom
total cost person care launch juli unitedhealthcar select follow lab particip
pln ameripath/dermpath biorefer genedx labcorp mayo clinic laboratori
lab select base rigor qualiti review process
chang lab access consum consum still use lab pln howev choos
lab pln may lead shorter wait time servic on-line schedul patient servic center higher qualiti care
lower cost
expect physician refer lab pln notic prompt turn-around time lab result ease-of-us
order lab electron well easi access physician-to-lab medic director consult support patient care
need anyth differ access servic provid particip pln
design unitedhealthcar provid directori
clearli much bigger opportun labcorp quest test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient old contract
allow region lab better penetr physician offic could arbitrag
benefit fact nation lab out-of-network one nation
payor drove higher price nation payor overal higher out-of-pocket
cost patient old payor paradigm drove complex physician would
field question patient around unexpect lab cost back in-
network remov unnecessari barrier compet nation lab
number get larg quickli current valuat believ investor
free call option potenti consolid upsid size outsid hospit lab
opportun around billion nation lab repres share everi
market share assum meaning price discount labcorp fee schedul
yield million addit revenu labcorp growth
estim labcorp estim increment margin would impli earn
growth around pull-through believ best outcom investor
lab industri consolid organ payor drive share nation
lab hand without need cash outlay
barclay laboratori corp america hldg
outsid hospit opportun
increment ep increment share gain
organ volum quarter grew y/i embed organ growth
weather benefit calendar impact along lost share
payor network estim underli util increas y/i
headwind manag care contract mute expect
labcorp post y/i declin rev-per-req ex-food sale attribut
pama partial off-set test mix also believ includ roughli
headwind fx believ test mix genom esoter test like help
off-set price headwind
note organ reimburs growth adjust fx beacon lb
labcorp adjust mix
share piepric discount labcorp fee scheduleincrement labcorp rev mm increment revenu growthinc barclay laboratori corp america hldg
covanc deliv gross organ growth total growth well
forecast said labcorp attribut miss time pass-through
revenu state organ revenu otherwis within compani full
year covanc guidanc labcorp confer call covanc presid john
ratliff affirm biopharma end market remain healthi compani
enthusiast integr offer consid covanc adj ebit
grew y/i came forecast believ
compani messag around pass-through time importantli fund environ
remain strong covanc see healthi demand area
compet book look littl softer quarter though compani continu
optimist around covanc competit market propos
transact envigo covanc ceo john ratliff note deal accret
earn margin year acquir envigo busi minim custom
overlap covanc mr ratliff view opportun increas cross-sel
covanc post ttm book-to-bil impli
quarterli book-to-bil around mark declin net book-to-
bill ultim believ could time impact book given
oper appear solid foot amidst healthi fund environ
manag continu enthusiast around integr offer elabor
success compani area clinic trial recruit joint analyt
companion diagnost develop commerci compani note
covanc integr offer key attract new custom
millionsestestestestestestestfisc year end dec labcorp metricstot growth organ growth dx metricsgross lab lab growth acquir total access organ net new weather calendar underli ppa beacon organ lab rev medicar pama overal y/i organ growth barclay laboratori corp america hldg
segment organ growth labcorp
labcorp complet rel modest quarter lab
industri pressur continu build believ nation lab leverag
scale advantag continu take share market organ growth
modest compani done effect job win new busi hospit
partnership acquisit continu believ effort provid better
healthcar integr patient cost share greater regul fda ldt
reimburs pressur pama driver share consolid toward
effici provid labcorp quest
us market continu fragment share repres
two independ market leader believ reimburs pressur drive lab
consolid smaller competitor lack scale drive effici busi
margin come increas pressur rel quieter deal
front activ year labcorp kick deal activ acquisit
mt sinai outreach oper follow sizabl paml acquisit ad
million refer lab test busi affili provid health system
organ growth labcorp dxcovanc drug independ affili barclay laboratori corp america hldg
cathol health initi quest activ year acquisit announc
total eight deal headlin million acquisition/partnership peacehealth
million acquisit medfusion/clearpoint texa
final sonic gotten action two jv nyu nyc
connecticut health network deal activ easili eclips million lab
industri revenu aggreg us industri revenu look
chart clear pace partnership acquisit
pick
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ last year partial
attribut pama uncertainti major driver thesi
industri updat reimburs laboratori test went effect januari
clearli mind industri particip hospit laboratori view
non-cor part health system ideal area hospit gener save
strike deal labcorp quest allow hospit focu core busi
continu provid patient access qualiti laboratori servic mani hospit
system alreadi financi pressur pama repres increment risk
drive manag team chang decision-mak
octob labcorp announc multi-year laboratori partnership
baptist health two organ build upon exist refer laboratori
arrang go five year expand
arrang includ technic servic labcorp provid enhanc
laboratori technolog data analyt help health system improv patient
care baptist health oper eight hospital-bas laboratori fall
scope agreement
yeardealslabtarget/partnerdatetyp medic center rmc orangeburg bynum patholog laboratori lab gener outreach medic outreach lab acquisitionquestoxford immunotec us lab lab lab acquisitionlabcorpappalachian region servicesquestcalifornia laboratori associ outreach acquisitionquestcleveland clinic servicesquesthartford outreach acquisitionquestshiel medic laboratori jvquestcap cod healthcar outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut health network venturequestmontefior health serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford health outreach acquisit barclay laboratori corp america hldg
march labcorp announc multi-year partnership appalachian
region healthcar labcorp provid technic servic appalachian region
healthcar hospital-bas lab refer test servic entir network
facil clinician labcorp also grant appalachian region healthcar access
enhanc inform technolog data analyt help improv deliveri
patient care appalachian region healthcar oper hospit kentucki
februari labcorp announc agreement acquir patholog
associ medic laboratori paml mark largest laboratori acquisit
notabl deal labcorp paml larg hospital-own laboratori
provid refer outreach test servic hospit partner asset
own jv provid servic provid cathol
initi chi two largest hospit system countri addit paml
labcorp also plan acquir lab interest number joint ventur
believ would ultim lead complet ownership busi announc
transact clearli valid labcorp commit expand partnership
anchor hospit system come close heel acquisit mt
sinai outreach busi acquisit expand labcorp presenc pacif
mid-west south give compani access serv two
largest health system
januari labcorp announc acquir clinic outreach
lab asset mount sinai health system nyc believ highlight
compani focu busi develop health system also repres
nice tuck-in acquisit compani system give labcorp access serv
anchor health system nyc market offer clinic patholog test
includ cytolog relat mdx test addit labcorp oper
mount sinai patient servic center psc region ad exist local
network psc opportun could includ collabor clinic trial
strengthen resourc covanc well work companion diagnost
medic educ term size estim transact could add
top line growth run-rat basi addit april
announc labcorp mount sinai enter contract
labcorp would work standard process test menu equip logist
health network seven acut care hospit
pama repres headwind quarterli lab revenu labcorp
continu expect full-year impact labcorp note aggreg
reimburs headwind consist compani expect
said compani expect reimburs pressur impact medicar revenu
medicaid ff manag medicaid collect repres around total
revenu remind implement major chang medicar reimburs
pama januari forecast cut across
compani medicar medicaid revenu financi impact meaning yet
manag given medicar clf repres labcorp diagnost
revenu total medicaid could drive total exposur total
revenu medicar reimburs chang actual sizabl survey work
interact lab director suggest industri experi period
meaning consolid ultim believ smaller lab outsiz medicar
exposur consolid time either organ inorgan benefit
labcorp quest industri leader
pleas see report
barclay laboratori corp america hldg
quot headlin medicar cut clf time roughli
code see rate decreas vs rate increas code
rate reduct greater labcorp quest estim around
top code see rate reduct annual first year reduct
increasingli sever routin test estim top
hcpc code clf spend cut altogeth top code
contribut clf spend almost million claim
design top code gener billion clf payment
top code cut genom health oncotyp dx top code
increas top code cut impli
medicar reimburs payment still weight median
averag addit anoth three test cut display magnitud
futur cut top code includ lipid panel reduct
code contribut nearli clf spend code drug
test def class new volum weight median pama reduct
overal continu believ signific rate reduct routin code
lead increas outsourc effici provid labcorp quest
barclay laboratori corp america hldg
top hcpc code clf spend
pleas see report
issu thought
pleas see report
takeaway clfs/pama
propos
potenti off-set horizon data collect
process similar process two import chang relat
definit applic lab influenc survey pool first chang
medicar advantag revenu exclud total medicar revenu threshold
second signific chang enabl hospit lab without uniqu npi
applic lab medicar revenu meet major
medicar revenu low expenditur threshold decis broaden definit
includ hospit lab come receiv much critic limit
hospit lab particip previou pama survey even addit hospit lab
particip still expect labcorp quest repres vast major data
submit part survey routin test though broader particip could
limit risk around addit cut clear chang view
expect medicar rate cut pama rate lock
data report period remind data report take place everi
year said think market may view posit given potenti
rate increas relief futur cut current model addit cut
labcorp report revenu billion y/i vs forecast
driven organ growth vs forecast acquir growth
divest growth food solut sale fx
labcorp dx revenu billion includ organ growth coupl
net divest headwind fx headwind drive overal growth
y/i came forecast estim volum growth
came estim organ volum
forecast y/i labcorp call includ impact
hcpc codehcpc code descriptiontot claim linestot payment total nlaweight median payment w/ payment w/ payment w/ thyroid stim metabol cbc w/auto diff hemoglobin test def panel total test def parathormon psa free culture/coloni test def test def natriuret colorect breast cbc folic acid suscept barclay laboratori corp america hldg
manag care network chang net impact well one fewer sell day
off-set favor weather impli underli util
quarter view solid result adjust covanc food
sale fx revenu per requisit y/i modestli better
forecast pama headwind within rev-per-req impli underli rev-
per-req strong
covanc revenu billion vs forecast
labcorp note exclud pass-through covanc organ revenu grew consist
full-year guidanc rang revenu decreas y/i organ
growth acquisit contribut off-set fx
ttm book-to-bil modestli ttm
believ impli quarterli book-to-bil roughli view
littl soft though time drive quarterli figur note labcorp
busi mix blend toward quicker burn revenu given central lab earli
develop exposur backlog grew y/i
quarterli revenu million organ growth
adjust ebit ex-amort declin y/i million adj ebit
margin percentag net revenu declin y/i
estim labcorp diagnost margin declin y/i
covanc drug develop margin improv diagnost adjust
oper incom impact pama million disposit busi
personnel cost cybersecur cost partial off-set launchpad save covanc
margin benefit volum leverag launchpad save acquisit fx partial
off-set higher personnel cost remind labcorp continu execut upon
launchpad initi labcorp compani announc phase launchpad
save expect covanc compani anticip
save million addit chiltern cost
synergi end
growth y/i barclay laboratori corp america hldg
adj ebit margin segment ex-corpor overhead
sg repres net revenu quarter estim
sg trend revenu
revenu lower expect ebitda margin
came expect due better cog partial off-set higher
expect sg expens
marginsebit sg abad debt lab barclay laboratori corp america hldg
margin trend revenu
flow oper came million modestli estim
million cffo repres adjust net incom quarter rel
expect stronger profit off-set greater expect
work capit headwind quarter capital-expenditure million repres net
revenu y/i capit deploy consist million share
repurchas modest debt repay million acquisit labcorp
repurchas million share deploy million toward labcorp
billion share repurchas author remain
labcorp continu gener signific free cash flow believ compani
flexibl activ capit deploy market compani
continu expect gener free cash flow rang million billion
million though note neg impact eurofin
tax payment million labcorp exit net debt ebitda
remind labcorp envigo privat announc trade
preclin asset appear strateg win-win specif labcorp
acquir envigo non-clin research servic busi envigo acquir
labcorp research model servic busi net-net labcorp agre pay
acquir revenu pro forma basi revenu
multipl estim purchas price also repres ttm ebitda
transact subject labor consult regulatori approv close condit
expect close within two month around end labcorp note
propos transact earn cash accret year one exceed
compani cost capit year math estim would repres around
accret full-year basi prior potenti synergi opportun full
thought transact pleas see report lh preclin trade
envigo strateg win-win
marginsebit margin barclay laboratori corp america hldg
use oper million
flowcapexlabcorp mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay laboratori corp america hldg
million except per share dataestestestestestestestfisc year end dec growth debt gross lab growth growth ex-fx organ growth increas gross cro net growth net margin net comp net net net intang loss equiti ebitda margin net net ebit margin net expens net debt pre-tax pre-tax incom tax net net average share average share ep ep increas item net incom adj net margin net increas dilut increas ebit adj ebit margin barclay laboratori corp america hldg
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
